Bosh sahifaARWR • NASDAQ
add
Arrowhead Pharmaceuticals Inc
22,12 $
Seans yopilganidan keyin:(0,00%)0,00
22,12 $
Yopilgan:26-apr, 17:49:02 (GMT-4) · USD · NASDAQ · Ogohlantirish
Yopilish kursi
21,87 $
Kunlik diapazon
21,72 $ - 22,36 $
Yillik diapazon
20,67 $ - 42,48 $
Bozor kapitalizatsiyasi
2,74 mlrd USD
Oʻrtacha hajm
987,86 ming
Narx/foyda
-
Dividend daromadliligi
-
Asosiy maydon
NASDAQ
Bozor yangiliklari
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
(USD) | dek, 2023info | Y/Y qiyosi |
---|---|---|
Daromad | 3,55 mln | -94,32% |
Joriy xarajat | 140,10 mln | 33,83% |
Sof foyda | -132,86 mln | -221,51% |
Sof foyda marjasi | -3,74 ming | -5 563,07% |
Har bir ulushga tushum | -1,24 | -217,95% |
EBITDA | -132,28 mln | -235,36% |
Amaldagi soliq stavkasi | 2,39% | — |
Balans
Jami aktivlari
Jami passivlari
(USD) | dek, 2023info | Y/Y qiyosi |
---|---|---|
Naqd pul va qisqa investitsiyalar | 213,38 mln | -56,85% |
Jami aktivlari | 626,29 mln | -29,75% |
Jami passivlari | 452,57 mln | -8,59% |
Umumiy kapital | 173,71 mln | — |
Tarqatilgan aksiyalar | 123,90 mln | — |
Narxi/balansdagi bahosi | 14,68 | — |
Aktivlardan daromad | -49,05% | — |
Kapitaldan daromad | -55,21% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
(USD) | dek, 2023info | Y/Y qiyosi |
---|---|---|
Sof foyda | -132,86 mln | -221,51% |
Operatsiyalardan naqd pul | -117,84 mln | -56,05% |
Sarmoyadan naqd pul | 64,84 mln | 180,35% |
Moliyadan naqd pul | 267,00 ming | -99,89% |
Naqd pulning sof oʻzgarishi | -52,68 mln | -155,89% |
Boʻsh pul | -168,71 mln | -59,25% |
Haqida
Arrowhead Pharmaceuticals is a publicly traded biopharmaceutical company based in Pasadena, California. Arrowhead’s products in development act through RNA interference mechanisms of action. The company focuses on treatments for hepatitis B, liver disease associated with alpha 1-antitrypsin deficiency and cardiovascular disease. The company has sixteen products in its pipeline, in various stages of development.
In 2015, the company substantially expanded its intellectual property holdings through complete acquisition of the full RNAi research and development portfolio, and assets from Novartis.
In April 2016, it was announced that the former company name, Arrowhead Research Corporation, will be changed to Arrowhead Pharmaceuticals, Inc.
In September 2016, Arrowhead entered into two collaboration and licensing agreements with Amgen. Under the deals, Amgen received a worldwide exclusive license to Arrowhead’s ARO-LPA RNAi program and an option to a worldwide exclusive license for ARO-AMG1, both for cardiovascular disease.
On Oct. 31, 2018, Arrowhead Pharmaceuticals Inc. closed on a $3.7 billion license and collaboration agreement with Janssen to develop and commercialize ARO-HBV. Wikipedia
Tashkil etilgan
1989
Xodimlar soni
525